Tambocor 100mg tablets

Држава: Велика Британија

Језик: Енглески

Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)

Активни састојак:

Flecainide acetate

Доступно од:

Dowelhurst Ltd

АТЦ код:

C01BC04

INN (Међународно име):

Flecainide acetate

Дозирање:

100mg

Фармацеутски облик:

Oral tablet

Пут администрације:

Oral

Класа:

No Controlled Drug Status

Тип рецептора:

Valid as a prescribable product

Резиме производа:

BNF: 02030200

Информативни летак

TBC
TAMBOCOR
® 50 MG & 100 MG TABLETS
Flecainide acetate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING
THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or
pharmacist.
• This medicine has been prescribed for you only. Do
not pass it on to others. It may harm them, even if
their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or
pharmacist. This includes any possible side
effects not listed in this leaflet. See section 4.
1. WHAT TAMBOCOR IS AND WHAT IT IS USED FOR
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TAMBOCOR
TABLETS
3. HOW TO TAKE TAMBOCOR TABLETS
4. POSSIBLE SIDE EFFECTS
5. HOW TO STORE TAMBOCOR TABLETS
6. CONTENTS OF THE PACK AND OTHER INFORMATION
WHAT TAMBOCOR IS AND WHAT IT IS USED FOR
Tambocor tablets belong to a group of medicines
called anti-arrhythmics. Anti-arrhythmics work by
controlling the rate and rhythm of the heart.
Tambocor tablets are used to treat:
• Arrhythmias (irregular heart beat)
• Tachycardia (heart beating too fast)
• Atrial fibrillation (rapid contractions of muscles in
the heart).
It is important for your doctor to treat these conditions
quickly and effectively in order to prevent more
serious heart problems from developing.
There are two strengths of tablet available, 50 mg and
100 mg.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE
TAMBOCOR TABLETS
DO NOT TAKE TAMBOCOR TABLETS IF YOU:
• are allergic to flecainide acetate or any of the other
ingredients of this medicine (listed in Section 6)
• have heart failure
• have cardiogenic shock (your heart is unable to
pump as much blood as your body needs)
• have heart block (your heart misses beats)
• have long-standing atrial fibrillation (rapid
contractions of muscles in the heart)
• have or have ever had any heart problems,
including problems with the valves in your heart or
conduction problems
• have sinus node dysfunction (a specific condit

Карактеристике производа

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Tambocor
®
100 mg tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 100 mg of flecainide acetate
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet
White, circular, biconvex tablet coded ‘TR100’on one face with a
break-line, and
‘3M’ on the other face.
The tablet can be divided into equal doses.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Tambocor tablets are indicated for:
a) AV nodal reciprocating tachycardia, arrhythmias associated with
Wolff-Parkinson-
White Syndrome and similar conditions with accessory pathways.
b) Paroxysmal atrial fibrillation in patients with disabling symptoms
when treatment
need has been established and in the absence of left ventricular
dysfunction (see
section 4.4 Special warnings and special precautions for use).
Arrhythmias of recent
onset will respond more readily.
c) Symptomatic sustained ventricular tachycardia.
d) Premature ventricular contractions and/or non-sustained ventricular
tachycardia
which are causing disabling symptoms, where these are resistant to
other therapy or
when other treatment has not been tolerated.
Tambocor tablets can be used for the maintenance of normal rhythm
following
conversion by other means.
Tambocor tablets are for oral administration.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults: Supraventricular arrhythmias: The recommended starting dosage
is
50mg twice daily and most patients will be controlled at this dose. If
required
the dose may be increased to a maximum of 300mg daily.
Ventricular arrhythmias: The recommended starting dosage is 100mg
twice
daily.
The maximum daily dose is 400mg and this is normally reserved for
patients
of large build or where rapid control of the arrhythmia is required.
After 3-5 days it is recommended that the dosage be progressively
adjusted to
the lowest level which maintains control of the arrhythmia. It may be
possible
to reduce dosage during long-term treatment.
Children: Tambocor i